Beit Jala Pharmaceutical Manufacturing

What Beit Jala Pharmaceutical Manufacturing does

Beit Jala Pharmaceutical Manufacturing (BJP) is a Palestinian public pharmaceutical manufacturer founded in 1969 as Jordan Chemical Laboratory and headquartered in Beit Jala, Bethlehem Governorate, West Bank. The company was re-registered as a public shareholding company in 2013 and trades on the Palestine Exchange under the ticker BJP. BJP manufactures 200+ generic pharmaceutical products across four dosage formats — solids, liquids, semi-solids, and sterile injectables — and holds GMP certifications from WHO (2007), JFDA (2008), EU GMP (2011), the Palestine Ministry of Health, and Poland, plus ISO 9001:2015 and ISO 14001:2015. The company is family-controlled, with the Sukhtian family as the principal shareholder group and Nidal Sukhtian serving as Chairman.

BJP operates a contract-manufacturing and own-brand distribution model, generating revenue primarily through one-time sales of pharmaceutical SKUs to pharmacies and authorized distributors, with a medical representative sales force driving B2B promotion. Revenue is split approximately 78.5% local Palestinian sales and 21.5% exports to around 11 countries including Jordan, Yemen, Algeria, Iraq, Tunisia, Oman, Macau-HK, Australia, Bolivia, and Equatorial Guinea. The company employs 216 staff and has signaled geographic expansion into Latin America starting with Chile, supported by an export facilitation partnership with Tasdeer (UK FCDO) and Cowater International, and an academic cooperation agreement with Al-Quds University.

The governance profile includes a November 2025 board restructuring triggered by the resignation of Al Nowat Investments, leading to an Extraordinary General Meeting to reconstitute the board. The company declared a 15% cash dividend for FY2025, signaling sustained cash generation. Customer-side concentration is distributed across retail pharmacies and wholesalers rather than a few large institutional buyers, but geographic concentration is high given the 78.5% dependence on the local Palestinian market.

Name

Beit Jala Pharmaceutical Manufacturing

Legal name

Beit Jala Pharmaceutical Company

Website

http://www.beitjalapharma.com

Company type

Public

Founded year

1970

Operating status

Operating

Headcount range

251–500 employees

Short description

Beit Jala Pharmaceutical Manufacturing is a Palestinian public generic drug manufacturer producing 200+ SKUs across four dosage formats, selling 78.5% locally and exporting to roughly 11 countries across MENA, Africa, and Asia-Pacific.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Medicine production
• Healthcare products
• Pharmaceutical tablets

Headquarters

HQ city

Palestine

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: BJP generates revenue through the manufacture and sale of pharmaceutical products. 78.5% of total sales on average are in the local Palestinian market; 21.5% of total sales on average come from exports to approximately 11 international markets in MENA region, Europe, Central Africa and Southeast Asia.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Beit Jala Pharmaceutical Manufacturing develops, produces, and markets more than 200 generic pharmaceutical products in four dosage-form categories: solids (tablets and capsules), liquids (syrups and suspensions), semi-solids (creams and ointments), and sterile dosage forms. The company manufactures its own formulations under GMP-certified conditions and sells them through domestic and export channels to pharmacies, hospitals, and government health authorities.

Product overview

Beit Jala Pharmaceutical Company (BJP) is a Palestinian pharmaceutical manufacturer founded in 1969, formerly known as Jordan Chemical Laboratory (JCL), producing more than 200 types of pharmaceutical products across four main categories: Solids (capsules, tablets, powders, caplets), Liquids (oral drops, syrups, solutions, suspensions, sprays), Sterile Products (ampoules, ear/nose drops, ear/nose ointments, eye drops), and Semi-Solids (creams, gels, lotions, suppositories, ointments, medicated shampoos). The company operates in accordance with international GMP standards and exports to MENA region, Europe, Central Africa, and Southeast Asia markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Solid dosage forms (tablets and capsules) Manufactured generic pharmaceutical solid dosage forms including tablets and capsules marketed under the company's brand portfolio, sold to pharmacies, hospitals, and public-sector health buyers in Palestine and export markets.
• Liquid dosage forms (syrups and suspensions) Manufactured generic pharmaceutical liquid dosage forms including syrups and oral suspensions, sold in Palestine and exported under the company's brand portfolio.
• Semi-solid dosage forms (creams and ointments) Manufactured generic pharmaceutical semi-solid topical dosage forms including dermatological creams and ointments, distributed to retail and institutional pharmaceutical buyers.
• Sterile dosage forms Manufactured sterile pharmaceutical dosage forms produced under EU GMP-aligned sterile manufacturing conditions, supplied to hospital and clinical buyers.

Quantifiable outcome

• 200+ pharmaceutical product types manufactured
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered minor and core.

• Jordan Export PartnersminorChannel Partner/ Reseller/ Distributor · 1 January 2010BJP started exporting to Jordan in 2010. Jordan is one of the top export destinations alongside Yemen, Algeria, Iraq, Tunisia, Oman, Macau-Hong Kong, Australia, Bolivia, and Equatorial Guinea.
• Al-Quds UniversitycoreStrategic or Co-development PartnerBeit Jala Pharmaceutical Company signed a joint cooperation agreement with Al-Quds University in the presence of Mr. Hamad Al-Masry, Vice Chairman of the Board of Directors, Dr. Walid Al-Kamel, General Manager, and Dr. Youssef Najajreh. The university was represented by its president, Dr. Imad Abu Kishk. The agreement embodies the partnership and cooperation between academia and industry.
• Tasdeer (Trade Facilitation and Customs Support Programme)coreStrategic or Co-development PartnerBJP is working with the Tasdeer programme (an official programme of the UK Foreign Commonwealth and Development Office, Contract No. PO10054, carried out in West Bank and Gaza) to expand and enter new export markets, improve production capacity, and implement an export growth plan. Tasdeer aims to improve Palestinian private sector competitiveness and the PA's capacity in trade, customs and import policy regulation.
• Cowater InternationalcoreStrategic or Co-development PartnerBeit Jala Pharmaceutical Company in cooperation with Cowater International, acting for the Tasdeer programme, is soliciting quotations for technical services and promotional activities. Cowater International is implementing the Trade Facilitation and Customs Support Programme (Tasdeer) on behalf of the UK FCDO.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Cipla: Indian-headquartered global generic pharmaceutical manufacturer with extensive emerging-market operations across MENA, Africa, and Asia. Competes against BJP for tenders in the same export geographies but operates at vastly larger scale with broader therapeutic depth.
• Hikma Pharmaceuticals: Largest Jordanian-origin generic and specialty pharmaceutical manufacturer with global operations and significantly broader portfolio, including injectables and branded generics. Comparable in product category and MENA heritage but operates at materially larger scale and across developed markets.

Direct peers

• EIPICO (Egyptian International Pharmaceutical Industries): Egyptian generic pharmaceutical manufacturer producing a wide range of dosage forms for local and export markets. Comparable in scale, product breadth, and focus on affordable generics for MENA and African tenders.
• SPIMACO Addwaeih: Saudi Arabian generic and branded pharmaceutical manufacturer producing a wide range of finished dosage forms. Comparable in formulation breadth, MENA footprint, and GMP-certified operations, though SPIMACO is significantly larger and has a stronger Saudi public-sector channel.
• Pharma International (Jordan): Jordan-based generic pharmaceutical manufacturer producing solids, liquids, and semi-solids for regional and export markets. Closely comparable to BJP in size, GMP positioning, and MENA-targeted channel strategy.
• Julphar (Gulf Pharmaceutical Industries): UAE-based generic pharmaceutical manufacturer producing tablets, capsules, syrups, creams, and sterile products for MENA, Africa, and Asia. Direct competitor in the affordable-generics segment targeting similar emerging-market tenders as BJP.
• Tabuk Pharmaceuticals: Saudi generic and specialty pharmaceutical company manufacturing a broad portfolio of finished dosage forms for MENA markets. Comparable in product breadth and regional export ambitions, with stronger Saudi government procurement relationships.
• Dar Al Dawa: Jordanian generic pharmaceutical manufacturer producing a broad portfolio of finished dosage forms for local and export markets across MENA. Closely comparable to BJP in scale, product breadth, and target export geographies, with overlapping GMP credentials and channel partners.
• Eva Pharma: Egypt-based pharmaceutical manufacturer producing generics and specialty products across solids, liquids, semi-solids, and sterile forms for MENA and Africa. Direct overlap in dosage form portfolio, target therapeutic categories, and emerging-market export focus.

Regional players

• Acdima (Arab Company for Drug Industries and Medical Appliances): Pan-Arab pharmaceutical holding with manufacturing interests across multiple MENA countries. Comparable as a regional generic manufacturer targeting the same institutional and government customers, though Acdima's footprint is broader and primarily Jordan-anchored.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/BJP_Pal

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beit Jala Pharmaceutical Manufacturing